These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 29035939)

  • 1. Predictors for the development of microalbuminuria and interaction with renal function.
    Chatzikyrkou C; Menne J; Izzo J; Viberti G; Rabelink T; Ruilope LM; Rump C; Mertens PR; Haller H
    J Hypertens; 2017 Dec; 35(12):2501-2509. PubMed ID: 29035939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.
    Haller H; Ito S; Izzo JL; Januszewicz A; Katayama S; Menne J; Mimran A; Rabelink TJ; Ritz E; Ruilope LM; Rump LC; Viberti G;
    N Engl J Med; 2011 Mar; 364(10):907-17. PubMed ID: 21388309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of microalbuminuria in patients with type 2 diabetes and hypertension.
    Menne J; Izzo JL; Ito S; Januszewicz A; Katayama S; Chatzykirkou C; Mimran A; Rabelink TJ; Ritz E; Ruilope LM; Rump LC; Viberti G; Haller H;
    J Hypertens; 2012 Apr; 30(4):811-8; discussion 818. PubMed ID: 22418908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
    Ritz E; Viberti GC; Ruilope LM; Rabelink AJ; Izzo JL; Katayama S; Ito S; Mimran A; Menne J; Rump LC; Januszewicz A; Haller H
    Diabetologia; 2010 Jan; 53(1):49-57. PubMed ID: 19876613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of cardiometabolic risk factors to estimated glomerular filtration rate decline in Indigenous Australians with and without albuminuria - the eGFR Follow-up Study.
    Barr EL; Barzi F; Hughes JT; Jerums G; O'Dea K; Brown AD; Ekinci EI; Jones GR; Lawton PD; Sinha A; MacIsaac RJ; Cass A; Maple-Brown LJ
    Nephrology (Carlton); 2018 Jul; 23(7):682-689. PubMed ID: 28503768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation.
    Menne J; Ritz E; Ruilope LM; Chatzikyrkou C; Viberti G; Haller H
    J Am Heart Assoc; 2014; 3(2):e000810. PubMed ID: 24772521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Resting Heart Rate on the New Onset of Microalbuminuria in Patients With Type 2 Diabetes: A Subanalysis of the ROADMAP Study.
    Schmieder RE; Bramlage P; Haller H; Ruilope LM; Böhm M;
    Medicine (Baltimore); 2016 Apr; 95(15):e3122. PubMed ID: 27082551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials.
    Mann JFE; Hansen T; Idorn T; Leiter LA; Marso SP; Rossing P; Seufert J; Tadayon S; Vilsbøll T
    Lancet Diabetes Endocrinol; 2020 Nov; 8(11):880-893. PubMed ID: 32971040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systolic blood pressure as a predictor of incident albuminuria and rapid renal function decline in type 2 diabetic patients.
    Sheen YJ; Lin JL; Li TC; Bau CT; Sheu WH
    J Diabetes Complications; 2014; 28(6):779-84. PubMed ID: 25219331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study.
    Kojima M; Okubo S; Mizubayashi R; Isaka N; Machida H; Okamoto S; Hirota H; Takeuchi M; Kato T; Nakatani K; Mizuno O; Miyagawa K; Makino K; Okura T; Dohi Y; Ito M; Kimura G
    Nephrol Dial Transplant; 2013 Jul; 28(7):1802-10. PubMed ID: 23535223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.
    Tofte N; Lindhardt M; Adamova K; Bakker SJL; Beige J; Beulens JWJ; Birkenfeld AL; Currie G; Delles C; Dimos I; Francová L; Frimodt-Møller M; Girman P; Göke R; Havrdova T; Heerspink HJL; Kooy A; Laverman GD; Mischak H; Navis G; Nijpels G; Noutsou M; Ortiz A; Parvanova A; Persson F; Petrie JR; Ruggenenti PL; Rutters F; Rychlík I; Siwy J; Spasovski G; Speeckaert M; Trillini M; Zürbig P; von der Leyen H; Rossing P;
    Lancet Diabetes Endocrinol; 2020 Apr; 8(4):301-312. PubMed ID: 32135136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Albuminuria in chronic heart failure: prevalence and prognostic importance.
    Jackson CE; Solomon SD; Gerstein HC; Zetterstrand S; Olofsson B; Michelson EL; Granger CB; Swedberg K; Pfeffer MA; Yusuf S; McMurray JJ;
    Lancet; 2009 Aug; 374(9689):543-50. PubMed ID: 19683640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial.
    Muskiet MHA; Tonneijck L; Huang Y; Liu M; Saremi A; Heerspink HJL; van Raalte DH
    Lancet Diabetes Endocrinol; 2018 Nov; 6(11):859-869. PubMed ID: 30292589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of estimated glomerular filtration rate and urine albumin-to-creatinine ratio with incidence of cardiovascular diseases and mortality in chinese patients with type 2 diabetes mellitus - a population-based retrospective cohort study.
    Fung CS; Wan EY; Chan AK; Lam CL
    BMC Nephrol; 2017 Feb; 18(1):47. PubMed ID: 28152985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Albuminuria and reduced glomerular filtration rate for predicting the renal outcomes in type 2 diabetic patients.
    Tanaka N; Babazono T; Takagi M; Yoshida N; Toya K; Nyumura I; Hanai K; Uchigata Y
    Nephrology (Carlton); 2015 Aug; 20(8):531-8. PubMed ID: 25773273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of multiple factorial intervention on ambulatory BP profile and renal function in hypertensive type 2 diabetic patients with overt nephropathy - a pilot study.
    Kanaoka T; Tamura K; Moriya T; Tanaka K; Konno Y; Kondoh S; Toyoda M; Umezono T; Fujikawa T; Ohsawa M; Dejima T; Maeda A; Wakui H; Haku S; Yanagi M; Mitsuhashi H; Ozawa M; Okano Y; Ogawa N; Yamakawa T; Mizushima S; Suzuki D; Umemura S
    Clin Exp Hypertens; 2011; 33(4):255-63. PubMed ID: 21699452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
    Haller H; Viberti GC; Mimran A; Remuzzi G; Rabelink AJ; Ritz E; Rump LC; Ruilope LM; Katayama S; Ito S; Izzo JL; Januszewicz A
    J Hypertens; 2006 Feb; 24(2):403-8. PubMed ID: 16508590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of dynamic renal resistive index (DRIN) for renal outcome in type 2 diabetes and essential hypertension: a prospective study.
    Bruno RM; Salvati A; Barzacchi M; Raimo K; Taddei S; Ghiadoni L; Solini A
    Cardiovasc Diabetol; 2015 May; 14():63. PubMed ID: 25994303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study).
    Januszewicz A; Ritz E; Viberti G; Mimran A; Rabelink AJ; Rump LC; Ruilope LM; Katayama S; Ito S; Izzo JL; Haller H
    J Hum Hypertens; 2011 Nov; 25(11):679-85. PubMed ID: 21150933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.